Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.
2.

Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.

Hui J, Przespo E, Elefante A.

J Oncol Pharm Pract. 2012 Jun;18(2):275-83. doi: 10.1177/1078155211420605. Epub 2011 Sep 26. Review.

PMID:
21956523
3.

Pralatrexate: basic understanding and clinical development.

Zain J, O'Connor O.

Expert Opin Pharmacother. 2010 Jul;11(10):1705-14. doi: 10.1517/14656566.2010.489552. Review.

PMID:
20509772
4.
5.

Molecular mechanisms of resistance to antifolates, a review.

Banerjee D, Ercikan-Abali E, Waltham M, Schnieders B, Hochhauser D, Li WW, Fan J, Gorlick R, Goker E, Bertino JR.

Acta Biochim Pol. 1995;42(4):457-64. Review.

6.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
7.

Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.

Foss FM.

Expert Opin Drug Metab Toxicol. 2011 Sep;7(9):1141-52. doi: 10.1517/17425255.2011.595404. Epub 2011 Jul 5. Review.

PMID:
21726160
8.

Methotrexate and Pralatrexate.

Wood GS, Wu J.

Dermatol Clin. 2015 Oct;33(4):747-55. doi: 10.1016/j.det.2015.05.009. Epub 2015 Aug 1. Review.

9.

Pralatrexate, a new hope for aggressive T-cell lymphomas?

Rueda A, Casanova M, Quero C, Medina-PĂ©rez A.

Clin Transl Oncol. 2009 Apr;11(4):215-20. Review.

PMID:
19380298
10.

Pharmacogenetics of methotrexate.

Krajinovic M, Moghrabi A.

Pharmacogenomics. 2004 Oct;5(7):819-34. Review.

PMID:
15469405

Supplemental Content

Support Center